Cargando…

Cellular Therapy in NSCLC: Between Myth and Reality

PURPOSE OF REVIEW: In this paper, we review the current state and modalities of adoptive cell therapies (ACT) in non-small cell lung carcinoma (NSCLC). We also discuss the challenges hampering the use of ACT and the approaches to overcome these barriers. RECENT FINDINGS: Several trials are ongoing i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imbimbo, Martina, Wetterwald, Laureline, Friedlaender, Alex, Parikh, Kaushal, Addeo, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Lung Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556121/ https://www.ncbi.nlm.nih.gov/pubmed/37646900 http://dx.doi.org/10.1007/s11912-023-01443-z

Ejemplares similares

The Role and Impact of Minimal Residual Disease in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2021)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Internal dose escalation is associated with increased local control for non-small cell lung cancer (NSCLC) brain metastases treated with stereotactic radiosurgery (SRS)
por: Abraham, Christopher, et al.
Publicado: (2017)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial)
por: Taylor, Sally, et al.
Publicado: (2021)

Targeted Therapies in Early Stage NSCLC: Hype or Hope?
por: Friedlaender, Alex, et al.
Publicado: (2020)

A New Generation of Vaccines in the Age of Immunotherapy
por: Addeo, Alfredo, et al.
Publicado: (2021)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
por: Friedlaender, Alex, et al.
Publicado: (2021)

Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
por: Parekh, Jay, et al.
Publicado: (2023)

Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review
por: Hall, Helen, et al.
Publicado: (2022)

Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
por: Eide, Hanne A., et al.
Publicado: (2018)

PD‐1/PD‐L1 Blockade Therapy in Advanced Non‐Small‐Cell Lung Cancer: Current Status and Future Directions
por: Xia, Liliang, et al.
Publicado: (2019)

Circulating tumour cells and circulating cell-free DNA in patients with lung cancer: a comparison between thoracotomy and video-assisted thoracoscopic surgery
por: Katopodis, Periklis, et al.
Publicado: (2021)

Implications for high-precision dose radiation therapy planning or limited surgical resection after percutaneous computed tomography-guided lung nodule biopsy using a tract sealant
por: de Groot, Patricia M., et al.
Publicado: (2017)

Uptake of minimally invasive surgery and stereotactic body radiation therapy for early stage non-small cell lung cancer in the USA: an ecological study of secular trends using the National Cancer Database
por: Blom, Erik F, et al.
Publicado: (2020)

MISSED TB DIAGNOSIS DURING THE COVID-19 PANDEMIC: MYTH OR REAL
por: GERBINO, GABRIELLE, et al.
Publicado: (2022)

Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
por: Wang, Xiaofei, et al.
Publicado: (2017)

Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review
por: Xiong, Wei, et al.
Publicado: (2023)

Practical Guidance for the Management of Adverse Events in Patients with KRAS(G12C)-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib
por: Zhang, Jun, et al.
Publicado: (2023)

Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials
por: Li, Lee X, et al.
Publicado: (2023)

Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer
por: Batra, Ullas, et al.
Publicado: (2023)

Prevalence and clinical characteristics of non-malignant CT detected incidental findings in the SUMMIT lung cancer screening cohort
por: Tisi, Sophie, et al.
Publicado: (2023)

Impact of radiographer immediate reporting of X-rays of the chest from general practice on the lung cancer pathway (radioX): a randomised controlled trial
por: Woznitza, Nick, et al.
Publicado: (2023)

Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer
por: Dubé-Pelletier, Maude, et al.
Publicado: (2023)

Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience
por: Altan, Mehmet, et al.
Publicado: (2023)

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRAS(G12C)-Mutant Non-Small Cell Lung Cancer
por: Elkrief, Arielle, et al.
Publicado: (2023)

Prevalence of pre-existing lung diseases and their association with income level among patients with lung cancer: a nationwide population-based case-control study in South Korea
por: Oh, Chang-Mo, et al.
Publicado: (2023)

Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration
por: Moore, Amanda M, et al.
Publicado: (2023)

Deep learning with test-time augmentation for radial endobronchial ultrasound image differentiation: a multicentre verification study
por: Yu, Kai-Lun, et al.
Publicado: (2023)

Rehabilitation outcomes for people with lung cancer (UNITE): protocol for the development of a core outcome set
por: Edbrooke, Lara, et al.
Publicado: (2023)

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape
por: Novello, Silvia, et al.
Publicado: (2023)

Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis
por: Wang, Chunsheng, et al.
Publicado: (2023)

Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study
por: Icht, Oded, et al.
Publicado: (2023)

Risk and prognostic factors of brain metastasis in lung cancer patients: a Surveillance, Epidemiology, and End Results population‑based cohort study
por: Hao, Yongping, et al.
Publicado: (2023)

Staging by Thoracoscopy in potentially radically treatable Lung Cancer associated with Minimal Pleural Effusion (STRATIFY): protocol of a prospective, multicentre, observational study
por: Ferguson, Jenny, et al.
Publicado: (2023)

Is investigation of patients with haemoptysis and normal chest radiograph justified?
por: Thirumaran, M, et al.
Publicado: (2009)

Virtual bronchoscopic navigation combined with endobronchial ultrasound to diagnose small peripheral pulmonary lesions: a randomised trial
por: Ishida, Takashi, et al.
Publicado: (2011)

UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer
por: Baldwin, D R, et al.
Publicado: (2011)

Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009
por: Lüchtenborg, Margreet, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7h48360ahlau6g1ccu2vgkn6bi